Search

Felix Biotechnology has been awarded a Small Business Innovation Research (SBIR) Phase I grant for $314,411 from the National Institute of Health (NIH) to develop a microfluidics platform for rapid, high-throughput screening of therapeutic

BiomX has reported findings from a phase 1a clinical trial of its K. pneumoniae-specific phage candidate BX002. They randomized 18 healthy adults to take either a phage cocktail or placebo orally. They looked at viable phage in stool, and c

Paper: Increased innate immune susceptibility in hyperpigmented phage-resistant mutants of P. aeruginosa.

Paper: Phage-antibiotic combination therapy for multidrug-resistant P. aeruginosa: In vitro synergy testing.

Paper: Whole-Genome analysis reveals that bacteriophages promote environmental adaptation of S. aureus via gene exchange, acquisition, and loss.

Hi everyone, after being virtual in 2021, our 2022 "Viral EcoGenomics and Applications" (VEGA) meeting is back in-person Oct 6 – 7, in the beautiful and sunny (although sometimes a bit foggy) Bay Area! (specifically on the Berkeley Lab camp

Hi everyone, after being virtual in 2021, our 2022 "Viral EcoGenomics and Applications" (VEGA) meeting is back in-person Oct 6 – 7, in the beautiful and sunny (although sometimes a bit foggy) Bay Area! (specifically on the Berkeley Lab camp

Video series: 3-part interview on phage therapy for recurrent UTI and beyond: Dr. Sabrina Green, Dr. Saima Aslam and Dr. Austen Terwilliger.

Hi everyone, after being virtual in 2021, our 2022 "Viral EcoGenomics and Applications" (VEGA) meeting is back in-person Oct 6 – 7, in the beautiful and sunny (although sometimes a bit foggy) Bay Area! (specifically on the Berkeley Lab camp

Drafting international guidelines for phage banks — initial brainstorming & organizational meeting We would like to gather a working group that will draft suggested guidelines over the coming months. This brainstorming meeting is open to a

The Phage Bites symposium is back! With student/ECR talks and expert guest panelists Keith Shearwin, Stefanie Barbirz and Michael J. McDonald discussing #phage #adaptive #strategies. Free to attend! 2nd Aug 2022. Online. Register and submit

Jon Iredell (Director of Phage Australia) & Jessica Sacher (Phage Directory) will take part in an interactive ‘Meet the Researcher’ webinar hosted by the WIMR Foundation on phage therapy for AMR infections, and the work they’re doing at Pha

The newly formed Belgian Society for Viruses of Microbes is excited to announce a 1-day inaugural symposium on Sept 23rd, 2022 in Leuven, Belgium! In parallel, the BSVoM team is guest-editing a special issue in Viruses. They call on all Be

News: LyseNTech, a Korean phage company led by Heejoon Myung, was named a leading research institute by the Korean Ministry of Trade, Industry and Energy. LyseNTech aims to develop 'LNT103', a phage-derived endolysin, as an inhaled treatmen

Paper: Evading while invading: induction of CRISPR-Cas by mucin as a mean to escape phages adhered to mucus.

Paper: Bacteriostatic effects of phage F23s1 and its endolysin on Vibrio parahaemolyticus.

Pre-print: The defence island repertoire of the Escherichia coli pan-genome.

Pre-print: Temperate phage-antibiotic synergy across antibiotic classes reveals new mechanism for preventing lysogeny.

Paper: Gut virome profiling identifies a widespread bacteriophage family associated with metabolic syndrome.

Paper: Effect of freeze drying, spray drying and electrospraying on the morphological, thermal, and structural properties of powders containing phage Felix O1 and activity of phage Felix O1 during storage.